60 research outputs found
A European Spectrum of Pharmacogenomic Biomarkers: implications for Clinical Pharmacogenomics
A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics
Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant interpopulation pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable pharmacogenomic biomarkers in 7 European populations, affecting drug efficacy and/ or toxicity of 51 medication treatment modalities. These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned. Also, our data demonstrate notable differences in predicted genotype-based warfarin dosing among these populations. Our findings can be exploited not only to develop guidelines for medical prioritization, but most importantly to facilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomic testing. This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, "select and shrink for summary statistics" (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28-1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08-1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21-1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29-1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35-1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs
Synthesis of messagenin and platanic acid chalcone derivatives and their biological potential
Reaction-activated palladium catalyst for dehydrogenation of substituted cyclohexanones to phenols and H 2
Recent advances in the applications of metal-ligand cooperation via dearomatization and aromatization of pincer complexes
Metal-ligand cooperation (MLC) has played an important role in the development of new green homogeneous catalytic reactions. In the past we have discovered a new mode of MLC which is based on the dearomatization and aromatization of pincer complexes and have utilized it to uncover new modes of bond activation and new catalytic reactions that are atom-economic, environmentally benign and sustainable. Building upon our earlier discoveries which have been well-reviewed in the past, this chapter discusses recent progresses on the application of the concept of MLC via dearomatization and aromatization of pincer complexes. Bond activation of greenhouse gases such as CO2 and N2O and their applications in the development of catalytic reactions have been discussed in detail. Additionally, the new concept of template catalysis where catalytic transformation occurs mainly on the pincer ligand and the metal centre acts as an “anchor” has also been discussed. Template catalysis utilizes the tool of MLC via dearomatization/aromatization to perform Michael reactions forming new C–C, C–O and C–N bonds catalysed by ruthenium, rhenium and manganese pincer complexes. © 2020, Springer Nature Switzerland AG
On the First Boundary Value Problem for Quasilinear Parabolic Equations with Two Independent Variables
The elusive abnormal CO2 insertion enabled by metal-ligand cooperative photochemical selectivity inversion
- …